What is Skye Bioscience, Inc. (SKYE) stock price today?

Skye Bioscience, Inc. (SKYE) is currently trading at $1.69, up 0.6% today.

What is SKYE P/E ratio?

Skye Bioscience, Inc.'s P/E ratio is -0.17. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SKYE return on equity (ROE)?

Skye Bioscience, Inc.'s return on equity (ROE) is -329.08%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Skye Bioscience, Inc.'s market cap?

Skye Bioscience, Inc. has a market capitalization of $7.42M.

NASDAQ · Biotechnology

Skye Bioscience, Inc. (SKYE) Stock

$1.69 +0.60% NASDAQ: SKYE Healthcare

Valuation

Metric	Value
Price	$1.69
Market Cap	$7.42M
P/E Ratio	-0.17
P/B Ratio	-16.76
P/S Ratio	0.00
EPS (TTM)	$-1.41
52-Week High	$14.08
52-Week Low	$1.50
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-329.08%
ROA	-457.62%
ROCE	-290.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.07
Current Ratio	3.38

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-8.0M	$-18.0M	$-35.0M	$-30.0M	$-58.0M
Net Profit	$-9.0M	$-19.0M	$-38.0M	$-27.0M	$-56.0M
EPS	$-40.00	$-70.16	$-42.96	$-5.84	$-11.28
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$10.0M	$9.0M	$12.0M	$73.0M	$28.0M
Total Liabilities	$4.0M	$12.0M	$14.0M	$5.0M	$8.0M
Cash	$9.0M	$1.0M	$1.0M	$68.0M	$6.0M
Borrowings	$2.0M	$2.0M	$5.0M	$0	$0

Latest News

The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea Yahoo Finance · Jul 17, 2026 Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 GlobeNewswire · May 20, 2026 UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update GlobeNewswire · May 12, 2026 Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update GlobeNewswire · May 11, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-6.0M	$-13.0M	$-14.0M	$-25.0M	$-43.0M
Investing Cash Flow	$0	$5.0M	$7.0M	$-2.0M	$-20.0M
Financing Cash Flow	$7.0M	$0	$0	$0	$0
Net Cash Flow	$7.0M	$-8.0M	$9.0M	$58.0M	$-63.0M
Free Cash Flow	$-7.0M	$-13.0M	$-14.0M	$-27.0M	$-43.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.01
EV / EBITDA	0.01
FCF Yield	-525.87%
Quick Ratio	0.95
Interest Coverage	-9439.02
Return 1Y	-83.79%
Return 3Y	-88.46%
Return 5Y	-98.53%

Ownership

Insiders Held1.17%

Institutions Held46.00%

Institutions Float Held46.55%

Institutional Holder	Shares	Report Date
5AM Venture Management, LLC	9,681,763	2026-03-31
Versant Venture Management, LLC	2,007,704	2026-03-31
Baker Bros. Advisors, LP	1,575,243	2026-03-31
Vanguard Capital Management LLC	764,457	2026-03-31
Sphera Funds Management Ltd.	678,928	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALGSAligos Therapeutics, Inc.	$5.34	+0.56%	-0.76	$33.05M	0.00%
BRNSBarinthus Biotherapeutics plc	$0.67	+4.69%	-0.41	—	0.00%
CVMCel-Sci Corporation	$1.94	-0.51%	-0.90	$13.33M	0.00%
INMBINmune Bio Inc.	$1.89	+3.28%	-2.81	$50.25M	0.00%
KZR	$7.29	+0.00%	-0.96	$53.86M	0.00%

About Skye Bioscience, Inc.

Skye Bioscience, Inc. is led by CEO Punit S. Dhillon, employs 16 people, headquartered in US, publicly traded since 2014.

Skye Bioscience, Inc. (SKYE) stock trades at $1.69 with a market capitalization of $7.42M. The stock is valued at a price-to-earnings (P/E) ratio of -0.17, price-to-book of -16.76, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.50 and $14.08, and currently trades 88.0% below its 52-week high.

On profitability, Skye Bioscience, Inc. generates a return on equity (ROE) of -329.08%, return on capital employed of -290.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides